Otsuka Pharmaceutical has shared positive results from a late-stage study of its investigational monoclonal antibody ...

Sobi and Apellis Pharmaceuticals have reported new results from the open-label period of the randomised Phase III VALIANT ...

Foamy urine could have a normal cause like rapid urination. But if it happens frequently, it could be caused by a medical ...

New 100-week data from the ongoing Phase I/II study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor, significantly reduced proteinuria in patients with immunoglobulin A nephropathy ...

A subanalysis of the NeflgArd study shows benefits in eGFR and urine protein-creatinine ratio at baseline and across ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving ...

Otsuka's experimental therapy for a potentially life-threatening kidney disease more than halved severe levels of protein in the urine of patients, intensifying the battle for an effective new ...